Mannavola Francesco, Mandala Mario, Todisco Annalisa, Sileni Vanna Chiarion, Palla Marco, Minisini Alessandro Marco, Pala Laura, Morgese Francesca, Di Guardo Lorenza, Stucci Luigia Stefania, Guida Michele, Indini Alice, Quaglino Pietro, Ferraresi Virginia, Marconcini Riccardo, Tronconi Maria Chiara, Rossi Ernesto, Nigro Olga, Occelli Marcella, Cortellini Alessio, Quadrini Silvia, Palmieri Giuseppe, Pigozzo Jacopo, Ascierto Paolo Antonio, Vitale Maria Grazia, Strippoli Sabino, Ferrucci Pier Francesco, Berardi Rossana, Randon Giovanni, Cardone Pietro, Schinzari Giovanni, Silvestris Franco, Tucci Marco
Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
Medical Oncology Unit, Department of Oncology and Hematology, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
Front Oncol. 2020 Sep 15;10:1652. doi: 10.3389/fonc.2020.01652. eCollection 2020.
We performed a multicenter retrospective observational study to investigate the impact of clinical-pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma.
A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician's practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs.
Eighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT.
Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.
我们开展了一项多中心回顾性观察研究,以调查临床病理特征和治疗策略对恶性黑色素瘤骨转移(BMs)患者并发症和生存的影响。
从19个意大利中心回顾性纳入了共305例有黑色素瘤且有BMs影像学证据的患者。所有患者均根据各自治疗医生的实践接受常规治疗。单变量和多变量模型均用于探讨黑色素瘤特征(包括骨相关事件[SREs])及不同治疗对总生存期(OS)和至SREs时间的影响。卡方检验评估了几个参数预测SREs发生的适用性。
83%的患者有异时性BMs。最常见(90%)的骨转移部位是脊柱,而45%的患者累及四肢骨骼。47%的患者经历了至少一次SRE,其中37%的病例接受了姑息性放疗(RT)。尽管接受骨靶向药物早期治疗的患者SREs发生风险降低62%且发生时间延迟,但没有黑色素瘤相关因素可预测SREs的发生。从骨转移诊断起的中位OS为10.7个月。多变量分析显示,BMs数量、转移器官数量、基线乳酸脱氢酶水平以及靶向治疗或免疫治疗为独立预后因素。亚组分析显示,接受免疫治疗和姑息性RT的患者亚组OS最佳(中位值 = 16.5个月)。
根据我们的结果,接受免疫治疗和姑息性RT的患者OS获益,提示可能存在相加效应。我们分析中观察到的骨靶向药物使用对SREs的明显保护作用值得进行前瞻性评估。